Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,121 stopped studies mapped to Lung Non-Small Cell Carcinoma and descendants · 90% state a reason
Over the 1,121 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05642195 | Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With… | Phase 1 / Phase 2 | suspended | Dec 8, 2022 | National Cancer Institute (NCI) | Revisions to eligibility/design being made prior to enrollment of first participants. | Enrollment / accrual |
| NCT06694454 | Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab… | Phase 1 / Phase 2 | suspended | Nov 19, 2024 | National Cancer Institute (NCI) | Placed on voluntary hold to new recruitment pending modification to combination monoclonal antibody… | Enrollment / accrual |
| NCT04405401 | Stereotactic Ablative Radiotherapy for Oligo-Progressive Non Small Cell Lung Cancer(SUPPRESS-NSCLC) | Phase 2 | terminated | May 28, 2020 | Centre hospitalier de l'Université de Montréal (CHUM) | Poor accrual | Enrollment / accrual |
| NCT06924606 | Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression… | Phase 2 | terminated | Apr 11, 2025 | Shanghai Junshi Bioscience Co., Ltd. | The research and development strategy was adjusted, so the research was suspended | Sponsor / business decision |
| NCT04844073 | A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer | Phase 1 / Phase 2 | terminated | Apr 14, 2021 | Takeda | Sponsor decision based on limited anti-cancer activity of TAK-186. | Sponsor / business decision |
| NCT05715229 | Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated…(G360-IIT) | Phase 2 | terminated | Feb 6, 2023 | Hackensack Meridian Health | Slow Accrual | Enrollment / accrual |
| NCT06714617 | Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors | Phase 1 | terminated | Dec 3, 2024 | SystImmune Inc. | The decision is based only on the Sponsor's internal portfolio prioritization and resource… | Safety / toxicity |
| NCT01720186 | Evaluation of a Pneumotachograph (SPI) for the Production of PET and CT Acquisitions…(SPI COHERENCE) | N/A | terminated | Nov 2, 2012 | Institut Claudius Regaud | not stated | Not stated |
| NCT04638751 | ARGONAUT: Stool and Blood Sample Bank for Cancer Patients | — | suspended | Nov 20, 2020 | Persephone Biosciences | Currently no funding to continue study. | Funding |
| NCT06616623 | Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell… | Phase 1 | suspended | Sep 27, 2024 | Dwight Owen | Pending ICF update | Other (stated, no rule matched) |
| NCT04738487 | Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475)… | Phase 3 | terminated | Feb 4, 2021 | Merck Sharp & Dohme LLC | Business Reasons | Sponsor / business decision |
| NCT05937074 | Metabolic Response to Food in Lung Cancer(METRIC) | — | terminated | Jul 10, 2023 | Pennington Biomedical Research Center | Poor accrual. | Enrollment / accrual |
| NCT06943664 | Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory,… | Phase 2 | withdrawn | Apr 24, 2025 | Roswell Park Cancer Institute | Lack of funding | Funding |
| NCT05226598 | Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With… | Phase 3 | terminated | Feb 7, 2022 | Merck Sharp & Dohme LLC | MK-7684A-007 was terminated early due to futility. A non-submission CSR, not intended to support… | Efficacy / futility |
| NCT06014827 | Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy… | Phase 2 | suspended | Aug 28, 2023 | City of Hope Medical Center | Budget Issue | Funding |
| NCT02129699 | Survival imProvement in Lung cancEr iNduced by DenOsUmab theRapy(SPLENDOUR) | Phase 3 | terminated | May 2, 2014 | ETOP IBCSG Partners Foundation | Completion of recruitment was not feasible as accrual was slower than anticipated. Even if a… | Enrollment / accrual |
| NCT05275868 | Study of MGY825 in Patients With Advanced Non-small Cell Lung Cancer | Phase 1 | terminated | Mar 11, 2022 | Novartis Pharmaceuticals | The trial was terminated due to a business decision and not as a result of any safety concerns | Safety / toxicity |
| NCT06405230 | Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular… | Phase 1 / Phase 2 | terminated | May 8, 2024 | GlaxoSmithKline | Operational challenges | Other (stated, no rule matched) |
| NCT06333678 | A Study Comparing Sotorasib With Durvalumab in People With Non-Small Cell Lung Cancer… | Phase 2 | terminated | Mar 27, 2024 | Memorial Sloan Kettering Cancer Center | Study closed by Amgen due to lack of enrollment | Enrollment / accrual |
| NCT05378763 | A Study of Poziotinib in Previously Treated Participants With Locally Advanced or…(PINNACLE) | Phase 3 | suspended | May 18, 2022 | Spectrum Pharmaceuticals, Inc | The study has not enrolled any patients. The study design is under discussion and will likely be… | Enrollment / accrual |
| NCT06982222 | Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have… | Phase 1 | withdrawn | May 21, 2025 | National Cancer Institute (NCI) | Other - Protocol moved to Withdrawn | Other (stated, no rule matched) |
| NCT07639242 | Olomorasib + Pembrolizumab KRAS G12C Mutant, PD-L1 TPS 1-49% Locally Advanced or… | Phase 2 | suspended | Jun 10, 2026 | UNC Lineberger Comprehensive Cancer Center | Administrative | Other (stated, no rule matched) |
| NCT06385262 | TOP 2301: Neoadjuvant Chemo for NSCLC | Phase 2 | suspended | Apr 26, 2024 | Duke University | Protocol is currently undergoing study design revisions and will re-open after amendment is IRB… | Other (stated, no rule matched) |
| NCT03606070 | Multiparametric PET-MRI Integration for a New Approach to Tumor Heterogeneity in…(IMAHTEP) | N/A | terminated | Jul 30, 2018 | Gustave Roussy, Cancer Campus, Grand Paris | Lack of inclusion | Other (stated, no rule matched) |
| NCT03987555 | Paclitaxel Therapeutic Drug Monitoring in Cancer Patients | — | suspended | Jun 17, 2019 | Wake Forest University Health Sciences | Funding | Funding |
| NCT03412058 | Identifying the Predictive Factors of Response to PD-1 or PD-L1 Antagonists(CHECK'UP) | N/A | terminated | Jan 26, 2018 | UNICANCER | The study was terminated prematurely due to insufficient patient recruitment | Enrollment / accrual |
| NCT06124118 | Tumor Treating Fields for Locally Advanced NSCLC(NOVOCURE) | Phase 1 | withdrawn | Nov 9, 2023 | University of Utah | Slow accrual | Enrollment / accrual |
| NCT07234799 | Feasibility Testing of a Dyadic Exercise Program for Patients Undergoing Thoracic… | N/A | suspended | Nov 18, 2025 | M.D. Anderson Cancer Center | PI Request | Other (stated, no rule matched) |
| NCT04797702 | Glumetinib Combined With Toripalimab in the Treatment of Relapsed or Metastatic Non-small…(CT32) | Phase 1 / Phase 2 | terminated | Mar 15, 2021 | Shanghai Junshi Bioscience Co., Ltd. | The company's research strategy was adjusted and the study was terminated | Sponsor / business decision |
| NCT03744715 | A Study to Allow Continued Dosing and/or Follow-up of Patients Who Have Had Previous… | Phase 2 | terminated | Nov 16, 2018 | Spectrum Pharmaceuticals, Inc | Business reasons, not related to safety. | Safety / toxicity |
| NCT05616624 | ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline… | Phase 1 / Phase 2 | terminated | Nov 15, 2022 | Washington University School of Medicine | Polaris has decided to close to accrual due to low enrollment | Enrollment / accrual |
| NCT05714553 | NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours | Phase 1 / Phase 2 | terminated | Feb 6, 2023 | NuCana plc | The NuTide:303 study was terminated at NuCana's discretion following refinement of the NUC-3373… | Sponsor / business decision |
| NCT06022757 | Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With… | Phase 1 / Phase 2 | terminated | Sep 5, 2023 | Evopoint Biosciences Inc. | Strategic decision by Sponsor. | Sponsor / business decision |
| NCT02546986 | Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic… | Phase 2 | terminated | Sep 11, 2015 | Celgene | not stated | Not stated |
| NCT03445000 | ALEctinib for the Treatment of Pretreated RET-rearranged Advanced Non-small Cell Lung…(ALERT-lung) | Phase 2 | terminated | Feb 26, 2018 | ETOP IBCSG Partners Foundation | Low recruitment rate | Enrollment / accrual |
| NCT03148327 | Astra Zeneca (Immuno Stereotactic Ablative Body Radiotherapy) ISABR Study: Randomized… | Phase 1 / Phase 2 | terminated | May 11, 2017 | Jonsson Comprehensive Cancer Center | Low accrual | Enrollment / accrual |
| NCT03425331 | Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC | Phase 2 | terminated | Feb 7, 2018 | Dana-Farber Cancer Institute | Slow accrual, competing studies, and lack of efficacy | Efficacy / futility |
| NCT04933695 | A Study of Sotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors Harbor a…(CodeBreaK201) | Phase 2 | terminated | Jun 22, 2021 | Amgen | Futility | Efficacy / futility |
| NCT05451849 | A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer | Phase 1 / Phase 2 | terminated | Jul 11, 2022 | TCR2 Therapeutics | No participants were enrolled in Phase 2 as Phase I was terminated early due to the lack of a clear… | Enrollment / accrual |
| NCT03114319 | Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors | Phase 1 | terminated | Apr 14, 2017 | Novartis Pharmaceuticals | Business reasons and not due to any safety concerns | Safety / toxicity |
| NCT06585488 | A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in… | Phase 1 | terminated | Sep 5, 2024 | BeOne Medicines | The Sponsor has made the decision to terminate this study due to the lack of promising efficacy,… | Efficacy / futility |
| NCT04585477 | Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E) | Phase 2 | suspended | Oct 14, 2020 | Stanford University | pending protocol amendment | Other (stated, no rule matched) |
| NCT06466187 | A Study of SGN-MesoC2 in Advanced Solid Tumors | Phase 1 | terminated | Jun 20, 2024 | Seagen, a wholly owned subsidiary of Pfizer | The trial was terminated for strategic reasons. The decision was not based on any safety concerns | Safety / toxicity |
| NCT05571839 | A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors | Phase 1 | terminated | Oct 7, 2022 | Seagen, a wholly owned subsidiary of Pfizer | The trial was terminated for strategic reasons. The decision was not based on any safety concerns. | Safety / toxicity |
| NCT05967533 | The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With… | Phase 1 | suspended | Aug 1, 2023 | University of California, Davis | For internal interim analysis | Efficacy / futility |
| NCT06191250 | --SuPERIOR Trial-- | Phase 2 | terminated | Jan 5, 2024 | University Health Network, Toronto | Study Terminated Prior to trial activation, due to changes in SOC of the treatment | Other (stated, no rule matched) |
| NCT03353428 | Intervention of Engineered Immune Effector T Cells Against Lung Cancer | Phase 1 / Phase 2 | withdrawn | Nov 27, 2017 | Shenzhen Geno-Immune Medical Institute | combine with NCT03356808 | Other (stated, no rule matched) |
| NCT07524257 | Phase 3 Study of Nogapendekin Alfa Inbakicept Plus Standard of Care vs Standard of Care… | Phase 3 | withdrawn | Apr 13, 2026 | ImmunityBio, Inc. | Sponsor decision | Sponsor / business decision |
| NCT03631199 | Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy…(CANOPY-1) | Phase 3 | terminated | Aug 15, 2018 | Novartis Pharmaceuticals | Results of primary analysis showed addition of canakinumab to combination treatment did not improve… | Safety / toxicity |
| NCT03318939 | Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20… | Phase 2 | terminated | Oct 24, 2017 | Spectrum Pharmaceuticals, Inc | Strategic business decision (unrelated to safety) | Safety / toxicity |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 17 hours agoSource updated Sep 29, 2026source: clinicaltrials